Kornimate/medical-research-clean huggingface dataset:
neonatal resuscitation with intact cord

Conditions: Intraventricular Hemorrhage

Summary: the purpose of this study is to examine whether providing ventilation during delayed umbilical cord clamping provides greater placental transfusion and improved hemodynamic transition at birth.

subjects will receive 1 minute of delayed cord clamping in both arms. one arm will receive routine care, warm dry and stimulate during the 1 minutes transfusion. the second arm will receive routine care plus administration of cpap and if need positive pressure ventilation. the outcome is to determine whether the addition of ventilation provides a larger placental transfusion and a smoother transition at birth.

Eligibility criteria:
inclusion criteria: * gestational age: women admitted 23+0 to 31+6 weeks (reason: highest risk for ivh) exclusion criteria: * gestational age: parents decline consent (reason: can only perform intervention at time of delivery) * congenital anomalies of newborn (reason: exclude the effect of abnormal hematological function) * placental abruption (reason: exclude pregnancies at risk for hemorrhage at the time of delivery) * twin to twin transfusion (reason: exclude possible loss of blood from other twin during delayed cord clamping) * placenta accreta * prolonged premature rupture of membranes (\> 2 weeks) prior to 23 weeks gestation

Keywords: delayed cord clamping pulmonary ventilation
safety of dtap-ipv-hep b-prp~t combined vaccine compared to tritanrix-hepb/hib™ and opv given at age 2, 4, and 6 months.

Conditions: Diphtheria; Tetanus; Pertussis; Haemophilus Influenzae Type b; Hepatitis B

Summary: to demonstrate that dtap-ipv-hb-prp\~t combined vaccine does not induce a higher incidence rate of high fever than tritanrix-hepb/hib™ and oral polio vaccine (opv) after any of the three vaccinations at 2, 4, and 6 months of age for each subject. to evaluate the overall safety in terms of: any solicited adverse reactions in the first 7 days after each injection, any adverse events and reactions in the first 30 days after each injection, any serious adverse events during the trial. immunogenicity: to document the immune response to hepatitis b antigen of the three batches of the investigational dtap-ipv-hb-prp\~t vaccine.


Eligibility criteria:
inclusion criteria: * 2 months old infants on the day of inclusion * born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg * informed consent form signed by one or both parents or by the legally acceptable representative and 1 or 2 independent witnesses * able to attend all scheduled visits and to comply with all trial procedures * has complied with the national immunization calendar (bcg for both countries) for the first 2 months of life. exclusion criteria: * participation in another clinical trial in the 4 weeks preceding the first trial vaccination * planned participation in another clinical trial during the present trial period * congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy * subjects with congenital or acquired immunodeficiency in the child's surrounding * systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances * chronic illness at a stage that could interfere with trial conduct or completion * blood or blood-derived products received since birth * any vaccination in the 4 weeks preceding the first trial vaccination * vaccination planned in the 4 weeks following the trial vaccination * documented history of pertussis, tetanus, diphtheria, poliomyelitis, haemophilus influenzae type b or hepatitis b infection(s) (confirmed either clinically, serologically or microbiologically) * mother known as seropositive for hiv or hepatitis c, or known carrier of hepatitis b surface antigen * previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, or haemophilus influenzae type b infection(s) * coagulopathy, thrombocytopenia or a bleeding disorder contraindicating im vaccination * history of seizures * febrile or acute illness on the day of inclusion.

Keywords: diphtheria tetanus pertussis recombinant hepatitis b poliomyelitis haemophilus influenzae type b tetanus protein
role of interleukin-6 and procalcitonin as novel inflammatory biomarkers in evaluating covid 19 disease severity - an experience at cmh quetta

Conditions: Covid19 Positive Patients

Summary: serum interleukin-6 and procalcitonin of 100 consenting covid 19 positive patients from april 2020 - may 2021 were assessed at pathology department cmh quetta and the results were correlated with severity of lung involvement on hrct chest

objective: to explore the relation between interleukin-6 and procalcitonin with covid severity on hrct chest study design: randomized control trial (clinical trials. gov identifier: nct04798391) place and duration of study: pathology, radiology \& ent department cmh quetta from april 2020 - may 2021 methodology: serum interleukin-6 and procalcitonin of 100 consenting covid 19 positive patients from april 2020 - may 2021 were assessed at pathology department cmh quetta and the results were correlated with severity of lung involvement on hrct chest results: serum interlukin-6 levels were raised in 97 (97%) patients with mean levels of 20.43 + 19.66 (pg/ml). serum procalcitonin levels were raised in 95 (95%) patients with mean levels of 0.4331 + 0.24 (ng/ml). a p value of \<0.001 was calculated on independent sample t-test for both serum interlukin-6 and serum procalcitonin as correlated with severity of lung involvement on hrct chest. conclusion: interlukin-6 and procalcitonin are excellent biomarkers for diagnosis and predicting severity of covid19 pneumonia. keywords: covid19 pneumonia, interlukin-6, procalcitonin.

Eligibility criteria:
inclusion criteria: * positive pcr of covid 19 exclusion criteria: * negative pcr of covid 19
mcg for risk stratifications of patients with chest pain

Conditions: Acute Coronary Syndrome

Summary: this prospective cohort study is aimed at identification and risk stratification of patients who have symptoms of acute chest pain suspected with acute coronary syndrome （acs） using magnetocardiography （mcg）.


Eligibility criteria:
inclusion criteria: * those with suspected acs who presented with symptoms of acute chest pain. * signed informed consent. exclusion criteria: * those with known structural heart disease such as cardiomyopathy and valvular disease; * those with atrial fibrillation, supraventricular tachycardia, atrioventricular block and other arrhythmias that have not returned to normal; * those who have chest pain with known pulmonary embolism or aortic coarctation; * those who are thought to be incapable of completing the mcg examination by an attending physician (or physician with higher qualifications) due to unstable clinical conditions, metal implants, etc; * those who are unable to perform magnetocardiography examinations due to claustrophobia, etc., or those who fail to receive magnetocardiography examination; * those with malignant tumors; * pregnant or lactating women. * those with acute or critical illnesses of other systems, such as acute or severe respiratory illnesses, marked abnormalities in liver function or kidney function.
long-term management of patients surgically treated for chronic pelvic pain by minimally invasive surgery

Conditions: Pelvic Pain

Summary: it is a retrospective observational study based on the analysis of the medical records of patients treated for chronic pelvic pain and benign gynecological pathologies at the gynecology unit of the university hospital of modena from 2010 to 2019. the aim of the study is to analyze the effects of medical and surgical treatments on chronic pelvic pain and associated pathologies.


Eligibility criteria:
inclusion criteria: * underwent minimally invasive gynecologic surgery from 2010 to 2019 * chronic pelvic pain * benign gynecologic disease (endometriosis, myoma, adenomyosis, pelvic organ prolapse exclusion criteria: * malignant gynecologic disease * chronic pelvic pain not linked to gynecologic disease

Keywords: pelvic pain endometriosis minimally invasive surgery
assessing the comparability of 2d and 4d ultrasound measurements

Conditions: Carpal Tunnel

Summary: investigators will recruit 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury. images will be captured twice, first with the 2d transducer and then with the 4d transducer and compared to images captured with the new 4d transducer, using the same movement data analysis protocols. investigators will also assess the inter and intrarater reliability of the 4d transducer images, by using two different sonographers, both trained in the technique, measuring the same blinded images on separate occasions, at least two weeks apart. the overall goal of this project is to assess the reliability, or reproducibility, of measurements in normal subjects using a novel 4d ultrasonographic method to characterize the subsynovial connective tissue (ssct) and detect motion between ssct, median nerve and tendon motion for the evaluation and diagnosis of patients with disorders affecting the carpal tunnel, especially carpal tunnel syndrome (cts).

cts can be diagnosed in many ways, but there are currently no non-invasive methods to assess the physiology within the carpal tunnel, which may help select treatment and predict treatment outcomes. the investigators have shown in preliminary work that differences in the motion of various structures within the carpal tunnel, including the median nerve, flexor tendons, and ssct, vary in normal subjects and those with cts. a clinical trial is already under way to assess conventional ultrasound imaging to predict outcomes of cts treatments. in this study investigators wish to compare the current ultrasound methods, which involve moving two dimensional images, with a new technology which captures moving images in three dimensions (i.e., four dimensions, or 4d). if successful, a single 4d measurement could replace longitudinal and transverse 2d images, saving time and allowing better understanding of the relationship between displacements in both planes.

Eligibility criteria:
inclusion criteria: • healthy volunteers exclusion criteria: * cervical radiculopathy * rheumatoid arthritis * osteoarthritis * flexor tendinitis * gout * hemodialysis * sarcoidosis * peripheral nerve disease * amyloidosis * traumatic injury - same arm
treating heart dysfunction related to cancer therapy with sacubitril/valsartan

Conditions: Heart Failure; Heart Dysfunction

Summary: to determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage b heart failure.

the current study will test the hypothesis that among adult age survivors of cancer diagnosed at age \< 39 years treatment of stage b heart failure with sacubitril-valsartan is feasible and safe.

Eligibility criteria:
inclusion criteria: * age \</= 39 years old at time of cancer diagnosis * clinical records adequate to determine diagnosis and treatment regimen * previous anthracycline chemotherapy * global longitudinal strain \<18% and/or * l vef below the institutional lower limit of normal but \>/=40% on echocardiogram or cardiac mri * no symptoms of heart failure (shortness of breath, fatigue, swelling). ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). exclusion criteria: * -age \<18 years * inability to obtain consent from patient or legally authorized representative * active acute or chronic psychiatric illness that in the opinion of the investigator may prevent compliance with study instructions * limited english or spanish proficiency that in the opinion of the investigator may prevent understanding the content of the informed consent form or safely completing the study procedures * participation in another concurrent intervention study within 30 days or treatment with an investigational drug within 5 half-lives prior to randomization * greater than mild mitral or aortic valve regurgitation/stenosis known pre-cancer therapy * severe kidney disease (gfr \<30 ml/min/1.73m2) * chronic hyperkalemia (\>5mmol/l) * evidence of covid-19 within the last 60 days or recent (21 days) exposure to close personal contact with covid-19. * greater than moderate tricuspid or pulmonary valve regurgitation/stenosis known pre-cancer therapy * hemodynamically significant congenital heart disease in the opinion of the investigator (not including pfo/small asd or small vsd) * greater than moderate pericardial effusion * constrictive cardiomyopathy diagnosed pre-cancer therapy * family history of genetic cardiomyopathy * evidence of infiltrative cardiomyopathy * symptomatic heart disease based on nyha classification * allergy to valsartan or sacubitril * inability to complete cmr or 6-minute walk test * inability to measure non-invasive blood pressure and heart rate in the ambulatory/home setting * pregnant/lactating * history of severe hypersensitivity reactions to gadolinium-based contrast agents (will perform limited cardiac imaging without contrast) * concomitant use of other ace inhibitors or arbs, aliskiren, nsaids or lithium or the inability to stop these medications for the study
short and optimal duration of dual antiplatelet therapy-3 study

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous coronary intervention (pci) using cobalt-chromium everolimus-eluting stents (cocr-ees, xiencetm) in patients with high bleeding risk or under the acute coronary syndrome patients.

in the previous trial, 1-month dual antiplatelet therapy (dapt) followed by clopidogrel monotherapy provided a net clinical benefit for the cardiovascular and bleeding events over 12-month dapt with aspirin and clopidogrel after cobalt-chromium everolimus-eluting stent (cocr-ees) implantation. however, even with very short dapt, the rate of bleeding at 1-year remained very high in other trials that enrolled the patients with high bleeding risk (hbr). notably, the risk of bleeding in patients with high bleeding risk (hbr) was particularly high within 1-month after percutaneous coronary intervention (pci) in previous cohort data, when dapt is implemented even in very short dapt regimen. more recently, in another trial, prasugrel monotherapy without aspirin immediately after successful stent implantation was associated with no stent thrombosis in selected patients with low risk stable coronary artery disease. aspirin-free strategy might be particularly beneficial in reducing bleeding in hbr patients. patients with acute coronary syndrome (acs) are also reported to be associated with higher risk for bleeding. therefore, we have planned a study to compare the cardiovascular and bleeding events at 1-month after pci using cocr-ees between no dapt strategy and 1-month dapt strategy in patients with hbr or acs.

Eligibility criteria:
inclusion criteria: * patients who are planned to have percutaneous coronary intervention with exclusive use of everolimus-eluting stent (xiencetm series). * patients with high bleeding risk defined by academic research consortium or acute coronary syndrome * patients who could take dual antiplatelet therapy with aspirin and p2y12 inhibitors for 1-month exclusion criteria: * patients who are judged to be unsuitable for participation by the principal investigator and co-investigator * patients with a known allergy to the study drugs * patients enrolled in the ongoing prospective interventional studies

Keywords: stent percutaneous coronary transluminal angioplasty bleeding antiplatelet agents
efficacy and safety of cortex eucommiae (ce: eucommia ulmoides oliver extract) in subjects with mild osteoarthritis

Conditions: Osteoarthritis

Summary: the purpose of this clinical trial is to evaluate the efficacy and safety of cortex eucommiae (ce: eucommia ulmoides oliver extract) in subjects with mild osteoarthritis (oa).

this is a 12-week, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of cortex eucommiae (ce: eucommia ulmoides oliver extract) in subjects with mild oa. one hundred subjects with mild oa will be recruited and randomly divided into 2 groups, each group will receive cortex eucommiae (ce: eucommia ulmoides oliver extract) or placebo and will take ce or placebo for 12 weeks. outcomes will be evaluated by self-administered questionnaires and lab test results. the hypothesis is that cortex eucommiae (ce: eucommia ulmoides oliver extract) which as a dietary supplementation may slow down or reverse oa.

Eligibility criteria:
inclusion criteria: * male or female 40 \~ 75 years of age * vas (visual analogue scale) over 30mm * kellgren \& lawrence grade i\~ii by x-ray * subject who agrees to participate in this clinical trial by themselves and signs the informed consent form (icf) exclusion criteria: * joint space under 2mm by x-ray * kellgren \& lawrence grade over iii with osteophyte, irregularly-shaped auricular surfaces, or subchondral bone cyst by x-ray * subjects who diagnosed inflammatory arthritis (rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, septic arthtritis, gout), or articulation fracture with abnormal values at esr and crp * subjects who diagnosed cardiovascular disease, immune disease, infectious diseases, tumor diseases * subjects having gastrointestinal diseases * uncontrolled hypertension patients (blood pressure ≥ 160/100mmhg) * uncontrolled diabetes melitusl patients (fasting glucose level ≥ 180mg/dl) * subjects have attended abnormal values at ast or alt (3 times excess at upper limit of the normal values) * subjects have attended abnormal values at creatinine (2 times excess at upper limit of the normal values) * pregnancy, breast-feeding, or subjects who have a plan to pregnancy within 3 months * use of osteoarthritis treatment drugs or dietary supplements within 2 weeks prior to screening * history of osteoarthritis treatment therapy within 2 weeks prior to screening * psychiatric disorder patient (schizophrenia, depressive disorder, drug abuse) * have participated in another clinical trial within the 3 months prior to screening * subjects who have hypersensitivity history about investigational product * have difficulty to be participated in this clinical trial by investigator's decision

Keywords: cortex eucommiae mild oa
supplementation with human chorionic gonadotropin (hcg) during controlled ovarian stimulation with recombinant follicle-stimulating hormone (fsh) for in vitro fertilisation

Conditions: Infertility

Summary: the purpose of this trial is to study whether addition of different doses of human chorionic gonadotropins during controlled ovarian stimulation for patients undergoing ivf will improve the number of top-quality embryos.


Eligibility criteria:
inclusion criteria: 1. females with indication for cos and ivf; 2. age between 25-37 years; 3. bmi \>18 and \< 30 kg/m2; 4. a regular menstrual cycle between 24 and 35 days and presumed to be ovulatory; 5. two ovaries; 6. tubal or unexplained infertility, including endometriosis stage i/ii; 7. a uterus consistent with expected normal function (e.g. no clinically interfering uterine fibroids) documented by transvaginal ultrasound at the screening; 8. male partner with sperm quality compatible with fertilization via ivf procedure or previous clinical pregnancy; 9. early follicular phase serum fsh levels of 1-12 iu/l; 10. early follicular phase total antral follicle (2-10mm) count ≥ 6; 11. confirmation of down-regulation before randomisation by transvaginal ultrasound; 12. willing and able to sign informed consent. exclusion criteria: 1. history of or current pcos, endometriosis stage iii/iv or severe male factor requiring icsi; 2. history of severe ovarian hyperstimulation syndrome (ohss); 3. presence of unilateral or bilateral hydrosalpinx at ultrasound; 4. more than three previously cos cycles; 5. previous poor response on an ivf-cycle, defined as \>20 days of gonadotrophin stimulation, cancellation due to limited follicular response or less than four follicles of ³15 mm diameter; 6. previous ivf cycle with unsuccessful fertilization, defined as fertilisation of £20% of the retrieved oocytes; 7. history of recurrent miscarriage; 8. fsh\>12iu/l or lh\>12ui/l (early follicular phase); 9. contraindications for the use of gonadotropins or gnrh analogues; 10. recent history of current epilepsy, hiv infection, diabetes or cardiovascular gastrointestinal, hepatic, renal or pulmonary disease; 11. pregnancy, lactation or contraindication to pregnancy; 12. current past (last 12 months) abuse of alcohol or drugs; 13. history of chemotherapy (except for gestational conditions) of radiotherapy; 14. undiagnosed vaginal bleeding; 15. tumours of the ovary, breast, adrenal gland, pituitary or hypothalamus and malformation of sexual organs incompatible with pregnancy; 16. abnormal karyotyping of the patient (if karyotyping is performed); 17. hypersensitivity to any trial product.

Keywords: hcg human chorionic gonadotropin
influence of intestinal microbiota implantation in preterm infants on microbiota and immune orientation at 3 years

Conditions: Infant, Premature

Summary: the main objective of this research is to study the links between changes in the intestinal microbiota (in terms of diversity) during the first 6 weeks of life for preterm infants and the presence / absence of a th1 immune status at 36 months of age.

the secondary objectives are to study the links between changes of the intestinal microbiota premature infants in terms of: * changing diversity of the microbiota in the first 6 weeks of life; * changes in the bacterial community (unifrac study) during the first 6 weeks of life; * diversity of the microbiota up to 6 weeks; -and- * diversity of the microbiota at 1, 2 \& 3 years; * bacterial communities (unifrac study) at 1, 2 \& 3 years; * lymphocyte subpopulation profiles at 3 years; * serum immunoglobulin a, g, m, e levels at 3 years; * history of infectious episodes, allergic and inflammatory episodes during the first 3 years of life. the links between certain variables known in the literature and neonatal microbiota will be confirmed / studied in our population: * mode of delivery; * length (and type) of antibiotic therapy in the neonatal period; * duration of breastfeeding.

Eligibility criteria:
inclusion criteria: * the parents of the patient (or legal guardian if any) have been informed about the implementation of the study, its objectives, its constraints, and patient rights * the parents of the patient (or legal guardian if any) must have given their free and informed consent and signed the consent form * the patient must be affiliated with or beneficiary of a health insurance plan * premature infants born at less than 33 weeks of gestation exclusion criteria: * the patient is participating in another interventional study (excepted " recherche du portage de clostridium butyricum et de toxines de clostridium chez les prématurés hospitalisés en néonatologie afin de prédire la survenue d'entérocolites nécrosantes", rcb 2016-a00-529-42 ; " betadose dose reduction of antenatal betamethasone given to prevent the neonatal complications associated with very preterm birth ", rcb 2016-001486-90. * it is not possible to correctly inform the parent (or legal guardian, if applicable) * a serious deformity or digestive malformation was diagnosed at birth * during the hospital stay in the neonatology department, the patient had a digestive disease requiring surgery (except necrotizing enterocolitis) * a transfer to another hospital is foreseen/predictable (eg, due to geographical distance)